Overexpression of the transcription factor MEF2D in hepatocellular carcinoma sustains malignant character by suppressing G2-M transition genes

Cancer Research

Volumn 74, Issue 5, 2014, Pages 1452-1462

  Ma, Leina ^a   Liu, Jia ^a   Liu, Limei ^a   Duan, Guangjie ^a   Wang, Qingliang ^a   Xu, Yanmin ^a   Xia, Feng ^a   Shan, Juanjuan ^a   Shen, Junjie ^a   Yang, Zhi ^a   Bie, Ping ^a   Cui, Youhong ^a   Bian, Xiu Wu ^a   Prieto, Jesus ^b,c   Avila, Matías A ^b,c   Qian, Cheng ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF NAVARRA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MEF2D PROTEIN; MICRORNA 122; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CDKN1A GENE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; G2 M TRANSITION GENE; GADD45A GENE; GADD45B GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MEF2D GENE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REGULATOR GENE; RPRM GENE; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HELA CELLS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MEF2 TRANSCRIPTION FACTORS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROGNOSIS; TRANSCRIPTION, GENETIC;

EID: 84896535861     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2171     Document Type: Article

References (42)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV-And HCV-Associated hepatocellular carcinoma. Nat Rev Cancer 2013;13:123-35.
3. Ranzani M, Cesana D, Bartholomae CC, Sanvito F, Pala M, Benedicenti F, et al. Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat Methods 2013;10:155-61.
4. Cleary SP, Jeck WR, Zhao X, Chen K, Selitsky SR, Savich GL, et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology. 2013 May 31. [Epub ahead of print].
5. Feng GS. Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. Cancer Cell 2012;21:150-4.
6. Molkentin JD, Olson EN. Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors. Proc Natl Acad Sci U S A 1996;93:9366-73.
7. McKinsey TA, Zhang CL, Olson EN. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci 2002;27:40-7.
8. Potthoff MJ, Olson EN. MEF2: a central regulator of diverse developmental programs. Development 2007;134:4131-40.
9. Lin Q, Schwarz J, Bucana C, Olson EN. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 1997;276:1404-7.
10. Arnold MA, Kim Y, Czubryt MP, Phan D, McAnally J, Qi X, et al. MEF2C transcription factor controls chondrocyte hypertrophy and bone development. Dev Cell 2007;12:377-89.
11. Hayashi M, Kim SW, Imanaka-Yoshida K, Yoshida T, Abel ED, Eliceiri B, et al. Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure. J Clin Invest 2004; 113:1138-48.
12. Mao Z, Bonni A, Xia F, Nadal-Vicens M, Greenberg ME. Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science 1999;286:785-90.
13. Flavell SW, Cowan CW, Kim TK, Greer PL, Lin Y, Paradis S, et al. Activity-dependent regulation of MEF2 transcription factors suppresses excitatory synapse number. Science 2006;311:1008-12.
14. Gaudilliere B, Shi Y, Bonni A. RNA interference reveals a requirement for myocyte enhancer factor 2A in activity-dependent neuronal survival. J Biol Chem 2002;277:46442-6.
15. Yang Q, She H, Gearing M, Colla E, Lee M, Shacka JJ, et al. Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science 2009;323:124-7.
16. Salma J, McDermott JC. Suppression of a MEF2-KLF6 survival pathway by PKA signaling promotes apoptosis in embryonic hippocampal neurons. J Neurosci 2012;32:2790-803.
17. Yao L, Li W, She H, Dou J, Jia L, He Y, et al. Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects. J Biol Chem 2012;287: 34246-55.
18. Prima V, Hunger SP. Cooperative transformation by MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins generated by the variant t(1;19) in acute lymphoblastic leukemia. Leukemia 2007;21:2470-5.
19. Prima V, Gore L, Caires A, Boomer T, Yoshinari M, Imaizumi M, et al. Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19)(q23; p13.3) in acute lymphoblastic leukemia. Leukemia 2005;19:806-13.
20. Homminga I, Pieters R, Langerak AW, de Rooi JJ, Stubbs A, Verstegen M, et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell 2011;19:484-97.
21. Schwieger M, Schuler A, Forster M, Engelmann A, Arnold MA, Delwel R, et al. Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C. Blood 2009;114:2476-88.
22. Lund AH, Turner G, Trubetskoy A, Verhoeven E, Wientjens E, Hulsman D, et al. Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat Genet 2002;32:160-5.
23. Suzuki T, Shen H, Akagi K, Morse HC, Malley JD, Naiman DQ, et al. New genes involved in cancer identified by retroviral tagging. Nat Genet 2002;32:166-74.
24. Li Y, Zhang L, Nong J, Bian S, Zhao Z, Ren Y, et al. [Expression of MEF2D on nasopharyngeal carcinoma tissues and its influence of prognostic]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2011;25:840-2.
25. Wang X, Tang X, Gong X, Albanis E, Friedman SL, Mao Z. Regulation of hepatic stellate cell activation and growth by transcription factor myocyte enhancer factor 2. Gastroenterology 2004;127: 1174-88.
26. Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 2007;131:1728-34.
27. Mamoon A, Ventura-Holman T, Maher JF, Subauste JS. Retinoic acid responsive genes in the murine hepatocyte cell line AML 12. Gene 2008;408:95-103.
28. Kojima S, Okuno M, Matsushima-Nishiwaki R, Friedman SL, Moriwaki H. Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (review). Int J Oncol 2004;24:797-805.
29. Shan J, Shen J, Liu L, Xia F, Xu C, Duan G, et al. Nanog regulates selfrenewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology 2012;56: 1004-14.
30. Ornatsky OI, McDermott JC. MEF2 protein expression, DNA binding specificity and complex composition, and transcriptional activity in muscle and non-muscle cells. J Biol Chem 1996;271: 24927-33.
31. Ma L, Liu J, Shen J, Liu L, Wu J, Li W, et al. Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell-cycle arrest of cancer cells. Cancer Biol Ther 2010;9:554-61.
32. Wong N, Lai P, Pang E, Leung TW, Lau JW, Johnson PJ. A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping. Hepatology 2000;32:1060-8.
33. Nishimura T, Nishida N, Itoh T, Komeda T, Fukuda Y, Ikai I, et al. Discrete breakpoint mapping and shortest region of overlap of chromosome arm 1q gain and 1p loss in human hepatocellular carcinoma detected by semiquantitative microsatellite analysis. Genes Chromosomes Cancer 2005;42:34-43.
34. Zhao M, Liu Y, Bao M, Kato Y, Han J, Eaton JW. Vascular smooth muscle cell proliferation requires both p38 and BMK1 MAP kinases. Arch Biochem Biophys 2002;400:199-207.
35. Kim Y, Phan D, van Rooij E, Wang DZ, McAnally J, Qi X, et al. The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. J Clin Invest 2008;118:124-32.
36. Takahashi T, Suzuki M, Shigematsu H, Shivapurkar N, Echebiri C, Nomura M, et al. Aberrant methylation of Reprimo in human malignancies. Int J Cancer 2005;115:503-10.
37. Ohki R, Nemoto J, Murasawa H, Oda E, Inazawa J, Tanaka N, et al. Reprimo, a new candidate mediator of the p53-mediated cell-cycle arrest at the G2 phase. J Biol Chem 2000;275:22627-30.
38. Wu Q, Qin SK, Teng FM, Chen CJ, Wang R. Lobaplatin arrests cellcycle progression in human hepatocellular carcinoma cells. J Hematol Oncol 2010;3:43.
39. Zhu N, Shao Y, Xu L, Yu L, Sun L. Gadd45-Alpha and Gadd45-gamma utilize p38 and JNK signaling pathways to induce cell-cycle G2-M arrest in Hep-G2 hepatoma cells. Mol Biol Rep 2009;36:2075-85.
40. Qiu W, David D, Zhou B, Chu PG, Zhang B, Wu M, et al. Downregulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma. Am J Pathol 2003;162:1961-74.
41. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently downregulated in human hepatocellular carcinoma. Cancer Res 2007; 67:6092-9.
42. Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z, et al. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell-cycle arrest. Cancer Lett 2011;310:160-9.